

ILLUMINA INC
Form SC 14D9/A
March 27, 2012

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14D-9

Solicitation/Recommendation Statement Under

Section 14(d)(4) of the Securities Exchange Act of 1934

(Amendment No. 9)

Illumina, Inc.

(Name of Subject Company)

Illumina, Inc.

(Name of Person Filing Statement)

Common Stock, \$0.01 par value

(Title of Class of Securities)

452327109

(CUSIP Number of Class of Securities)

Christian G. Cabou

Senior Vice President & General Counsel

Illumina, Inc.

5200 Illumina Way

San Diego, CA 92122

(858) 202-4500

**(Name, address and telephone number of person authorized to receive notices and
communications on behalf of the person filing statement)**

With a copy to:

Frederick W. Kanner

Dewey & LeBoeuf LLP

1301 Avenue of the Americas

New York, New York 10019

(212) 259-7300

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Amendment No. 9 to Schedule 14D-9 (this Amendment) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended from time to time, the Statement) originally filed by Illumina, Inc., a Delaware corporation (Illumina), with the Securities and Exchange Commission (SEC) on February 7, 2012, relating to the tender offer by CKH Acquisition Corporation, a Delaware corporation (Purchaser) and an indirect wholly owned subsidiary of Roche Holding Ltd, a joint stock company organized under the laws of Switzerland (Roche), to purchase all outstanding shares of Illumina common stock, par value \$0.01 per share, together with the associated preferred stock purchase rights, for \$44.50 per share, net to the seller in cash, without interest and less applicable withholding taxes.

Except as specifically noted herein, the information set forth in the Statement remains unchanged. Capitalized terms used in this Amendment without definition have the respective meanings set forth in the Statement.

ITEM 4. The Solicitation or Recommendation.

Item 4 of the Statement is hereby amended and supplemented by adding the following text immediately before the caption Reasons for Recommendation on page 20 of the Statement:

On March 19, 2012 and March 20, 2012, Purchaser and Roche filed their definitive proxy statement with the SEC.

ITEM 9. Exhibits.

Item 9 of the Statement is hereby amended and supplemented by adding the following exhibits:

Exhibit No.	Description
(a)(27)	Amended and Restated Letter to Illumina's Stockholders, dated March 19, 2012 (incorporated by reference to the Schedule 14A filed with the SEC by Illumina on March 26, 2012)
(a)(28)	Letter to Illumina's Stockholders, dated March 26, 2012 (incorporated by reference to the Schedule 14A filed with the SEC by Illumina on March 27, 2012)
(a)(29)	Press Release issued by Illumina, dated March 26, 2012, disclosing the Letter to Illumina's Stockholders (incorporated by reference to the Schedule 14A filed with the SEC by Illumina on March 26, 2012)
(a)(30)	Press Release issued by Illumina, dated March 26, 2012, relating to the extension of the Offer (incorporated by reference to the Schedule 14A filed with the SEC by Illumina on March 27, 2012)

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

ILLUMINA, INC.

By: /s/ Christian G. Cabou
Name: Christian G. Cabou
Title: Senior Vice President & General Counsel

Dated: March 27, 2012

EXHIBIT INDEX

Exhibit No.	Description
(a)(27)	Amended and Restated Letter to Illumina's Stockholders, dated March 19, 2012 (incorporated by reference to the Schedule 14A filed with the SEC by Illumina on March 26, 2012)
(a)(28)	Letter to Illumina's Stockholders, dated March 26, 2012 (incorporated by reference to the Schedule 14A filed with the SEC by Illumina on March 27, 2012)
(a)(29)	Press Release issued by Illumina, dated March 26, 2012, disclosing the Letter to Illumina's Stockholders (incorporated by reference to the Schedule 14A filed with the SEC by Illumina on March 26, 2012)
(a)(30)	Press Release issued by Illumina, dated March 26, 2012, relating to the extension of the Offer (incorporated by reference to the Schedule 14A filed with the SEC by Illumina on March 27, 2012)